A phase II, randomised, double-blind, parallel-group, placebo-controlled, multi-centre study to assess the efficacy and safety of once-daily orally administered ZD4054 15 mg and 10 mg doses in pain-free or mildly symptomatic patients with prostate cancer and bone metastases, who have rising serum prostate specific antigen (PSA) levels despite medical or surgical castration
- Registry ID
- EUCTR2004-000344-24
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- AstraZeneca AB
- Start date
- 2004-07-06
- Completion date
- 2009-02-25
- Last update
- 2026-08-16
Conditions
- Hormone-refractory prostate cancer
Summary
The primary objective of the study is to assess the effect of ZD4054 on time to progression in metastatic hormone refractory prostate cancer, which will recommend a dose of ZD4054 for use in future studies.
Locations
- , , Finland
- , , Sweden
- , , Denmark
- , , UK
View on source registry